EPH–International Journal of Biological & Pharmaceutical Science
Published by: **Southern Cross Academic Press**
ISSN (Online): **2208-2166**
Volume 12 Issue 01 June 2026
DOI: https://doi.org/10.69980/awz0xr24

Dysbiosis And Dementia: Unraveling The Microbial Imbalance In Alzheimer's Disease

[1*]Dr. Priyanka N, [2]N Divya, [3]E Ishwarya, [4]M Pavithra, [5]P Subash, [6]V.S.Tejasri

[1*]Assistant professor, Department of Pharmacology, GRT Institute of Pharmaceutical Education and Research, Tiruttani, Tiruvallur, Tamil Nadu, India, Email Id: priyanka213111@gmail.com, Orcid Id: 0009-0001-2050

[2]Student, GRT Institute of Pharmaceutical Education and Research, Tiruttani, Tiruvallur, Tamil Nadu, India, Email Id: divyan9944@gmail.com, Orcid Id: 0009-0005-7352-9719

[3]Student, GRT Institute of Pharmaceutical Education and Research, Tiruttani, Tiruvallur, Tamil Nadu, India, Email Id: ishwaryaeswar1627@gmail.com, Orcid Id: 0009-0005-7586-051X

[4]Student, GRT Institute of Pharmaceutical Education and Research, Tiruttani, Tiruvallur, Tamil Nadu, India, Email Id: Pavithra.nvd@gmail.com, Orcid Id: 0009-0006-4665-1556

[5]Student, GRT Institute of Pharmaceutical Education and Research, Tiruttani, Tiruvallur, Tamil Nadu, India, Email Id: subashmonster18@gmail.com, Orcid Id: 0009-0006-0824-0959

[6]Student, GRT Institute of Pharmaceutical Education and Research, Tiruttani, Tiruvallur, Tamil Nadu, India, Email Id: Vstejasri@gmail.com, Orcid Id: 0009-0000-8363-2553

***Corresponding author**: Dr. Priyanka N (priyanka213111@gmail.com)

Article History:
Received : 2026-05-05
Revised : 2026-05-20
Accepted : 2026-06-09
Published : 2026-06-25

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, and hallmark pathological features such as amyloid-β plaque accumulation and tau protein hyperphosphorylation. While traditional research has primarily focused on central nervous system mechanisms, emerging evidence highlights the critical role of the microbiota–gut–brain axis (MGBA) in modulating the onset and progression of AD. The gut microbiota, a complex and dynamic community of microorganisms, interacts with the brain through neural, immune, endocrine, and metabolic pathways, thereby influencing brain function and homeostasis.

In healthy conditions, the gut microbiome maintains physiological balance by producing essential metabolites such as short-chain fatty acids (SCFAs), tryptophan derivatives, and bile acids, which regulate immune responses, neurotransmission, and blood–brain barrier (BBB) integrity. However, dysbiosis—an imbalance in gut microbial composition—has been strongly associated with AD. It is characterized by reduced microbial diversity, increased pro-inflammatory bacteria, and decreased beneficial metabolites. These alterations contribute to systemic inflammation, neuroinflammation, BBB disruption, oxidative stress, and mitochondrial dysfunction, all of which accelerate neurodegenerative processes.

Mechanistically, dysbiosis promotes activation of microglia and astrocytes, leading to chronic neuroinflammation and increased production of inflammatory cytokines. It also enhances

amyloid-β deposition and tau pathology through inflammatory signaling, oxidative damage, and impaired clearance mechanisms. Furthermore, compromised BBB integrity allows harmful microbial products such as lipopolysaccharides (LPS) to enter the brain, exacerbating neuronal damage. Lifestyle and environmental factors—including diet, aging, stress, and medication use—further influence gut microbiota composition and contribute to disease progression.

Recent studies from both human and animal models provide strong evidence supporting the role of gut microbiota in AD pathogenesis and highlight potential microbial biomarkers for early detection. Therapeutic strategies targeting the gut microbiome, such as probiotics, prebiotics, fecal microbiota transplantation (FMT), dietary interventions (e.g., Mediterranean and ketogenic diets), and modulation of microbial metabolites, show promising results in reducing neuroinflammation and improving cognitive function.

Despite these advancements, challenges remain in establishing causality, standardizing methodologies, and translating preclinical findings into clinical practice. Future research integrating multi-omics approaches and artificial intelligence is essential for identifying precise mechanisms and developing personalized microbiome-based therapies.

In conclusion, gut microbiota dysbiosis plays a pivotal role in Alzheimer's disease through interconnected pathways involving inflammation, metabolic dysfunction, and neuronal damage. Targeting the gut–brain axis offers a novel and promising direction for early diagnosis, prevention, and treatment of AD, potentially improving patient outcomes and quality of life.

Keywords: Alzheimer's Disease, Microbiota–Gut–Brain Axis, Blood–Brain Barrier, Neuroinflammation; Amyloid-β Pathology; Microbiome-Based Therapeutics.ss

1. Introduction

1.1 Overview of Alzheimer's disease

Alzheimer's disease (AD) represents the most prevalent form of dementia worldwide, accounting for 60–70% of all dementia cases and affecting an estimated 7.2 million Americans aged 65 and older as of 2025[1]. This progressive neurodegenerative disorder is characterized by an insidious decline in cognitive function, memory impairment, and behavioral changes that ultimately hold up individuals of their independence and quality of life[2][3]

The global burden of AD continues to increase dramatically, with prevalence among adults aged 65 and above increasing by 160% between 1991 and 2021, rising from 18.7 million to 49 million cases worldwide[2]. Without effective disease-modifying interventions, projections indicate that the number of affected Americans could reach 13.8 million by 2060, representing a tough public health challenge[2]

The neuropathologic properties of AD have been well-established through decades of research and include the extracellular accumulation of amyloid-beta (Aβ) plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein[2] [5].

According to the amyloid cascade hypothesis, Aβ pathophysiology represents an upstream event that triggers a deleterious cascade involving tau pathology, synaptic dysfunction, neuroinflammation, and ultimately neurodegeneration[5].

Recent evidence suggests that Aβ and tau pathology exert synergistic effects on neurophysiology and cognitive decline, with Aβ facilitating the spread of tau beyond the mesial temporal lobe and precipitating accelerated cortical neurodegeneration[5]. The temporal relationship between these pathological processes indicates that cortical Aβ deposition may precede tau pathology by approximately 10 years before clinical symptom onset[5]

Despite substantial research investment, the upstream modulators of AD pathology remain incompletely understood, and therapeutic strategies targeting Aβ and tau have yielded disappointing clinical results[2] This therapeutic failure has prompted researchers to explore alternative mechanistic pathways that may contribute to disease initiation and progression. The economic and societal burden of AD is staggering, with annual per capita costs ranging from $468 to $171,284 depending on regional healthcare differences, and unpaid caregivers providing an estimated 18.4 billion hours of care annually[5].

As the global population ages, addressing the AD epidemic requires innovative approaches that target novel therapeutic pathways identified through rigorous mechanistic investigation.

1.2 The emerging role of the gut-brain axis

Structure and FunctionOver the past decade, accumulating evidence has positioned the microbiota-gut-brain axis (MGBA) as a critical bidirectional communication system that profoundly influences brain development, function, and behavior[8] [9] [10]. This axis represents a complex network of interactions between the gastrointestinal tract and the central nervous system (CNS), mediated through neural, endocrine, immune, and metabolic pathways[11][8].

The MGBA encompasses the gut microbiota, the enteric nervous system (ENS), the autonomic nervous system (ANS), the hypothalamic-pituitary-adrenal (HPA) axis, and the CNS, creating an integrated system that maintains homeostasis across multiple physiological domains[10][12].The structural foundation of the MGBA involves multiple interconnected components. The ENS, often referred to as the "second brain," contains between 200 and 600 million neurons organized into myenteric and submucosal plexuses that span the gastrointestinal tract from esophagus

to rectum[13][14].
This sophisticated neural network can operate independently of the CNS while maintaining bidirectional communication through the vagus nerve, which serves as a primary conduit for gut-to-brain signaling[15][10].
The ENS integrates sensory information regarding gut contents, distension, and microbial metabolites, and coordinates motor and secretory responses that regulate digestive function[13]. Importantly, the ENS represents the first interface between intestinal microorganisms and the nervous system, positioning it as a critical mediator of microbiota-brain communication[13].
The blood-brain barrier (BBB) constitutes another essential component of the MGBA, functioning as a highly selective barrier between the peripheral circulation and the CNS[16][17]. Comprised f brain endothelial cells connected by tight junction proteins (claudin, occludin, and zona occludens-1), the BBB maintains brain homeostasis by regulating the influx and efflux of substances while restricting the entry of potentially harmful molecules and cells[16][18]
The integrity of the BBB is critically dependent on interactions with perivascular cells including pericytes, astrocytes, microglia, and oligodendrocytes, collectively forming the neurovascular unit[16][17]. Emerging evidence indicates that gut microbiota-derived metabolites, particularly short-chain fatty acids (SCFAs), can directly influence BBB integrity by modulating tight junction protein expression and reducing inflammatory responses[19][20]

1.3. Key players: Microbiota, immune system, ens, and cns

The gut microbiota represents a diverse ecosystem comprising trillions of microorganisms, including bacteria, fungi, and viruses, that establish residence in the gastrointestinal tract from birth[21][22] In healthy adults, the gut microbiome exhibits high taxonomic diversity and gene richness, with bacterial composition dominated by the phyla Bacteroidota (formerly Bacteroidetes) and Bacillota (formerly Firmicutes), which collectively account for approximately 90% of gut bacteria[21][23]
Other significant phyla include Actinobacteriota, Pseudomonadota (formerly Proteobacteria), and Verrucomicrobiota, though their relative abundances vary considerably between individuals[21][24]. At the species level, Faecalibacterium prausnitzii, a butyrate-producing member of the Firmicutes phylum, represents one of the most abundant commensal bacteria in healthy adults[24][23].
The functional repertoire of the gut microbiota extends far beyond nutrient metabolism to encompass critical roles in immune system development, pathogen resistance, vitamin synthesis, and neurotransmitter production[9][22].
The microbiota performs essential metabolic functions through approximately 5 million microbial genes, providing unique enzymatic capabilities that enable the breakdown of complex dietary polysaccharides into bioactive metabolites[22].
These metabolites, including SCFAs (acetate, propionate, and butyrate), tryptophan derivatives (indole, indole-3-acetic acid, and indole-3-propionic acid), and bile acids, serve as key signaling molecules that modulate host physiology and brain function[9][19][25].The immune system represents a critical mediator of microbiota-gut-brain communication, with gut bacteria playing fundamental roles in immune system maturation and function[9][26].
Intestinal microbes interact with both innate and adaptive immune cells through pattern recognition receptors, influencing the production of pro-inflammatory and anti-inflammatory cytokines that can affect brain function[9][27] Microbial metabolites modulate immune cell differentiation, with SCFAs promoting the development of regulatory T cells and suppressing pro-inflammatory responses[19][26].
The gut-associated lymphoid tissue serves as the largest immune organ in the body, housing approximately 70% of the body's immune cells and serving as a critical

interface between the microbiota, immune system, and systemic circulation[26].Communication between the microbiota and the CNS occurs through multiple interconnected pathways. The vagal pathway provides direct neural communication, with gut bacteria and their metabolites stimulating afferent neurons of the ENS that project to the brainstem via the vagus nerve[15][9]. The endocrine pathway involves microbial modulation of enteroendocrine cells, which produce hormones such as glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) that influence satiety, metabolism, and brain function[12].
Recent discoveries have revealed that enteroendocrine L cells form direct synaptic connections (neuropods) with the ENS, enabling rapid gut-to-brain signaling within milliseconds[12]. The immune pathway involves microbial regulation of cytokine production and immune cell activation, which can influence neuroinflammation and BBB permeability[9][12]. Finally, the metabolic pathway encompasses bacterial production of neuroactive compounds, including neurotransmitters (serotonin, GABA, dopamine), SCFAs, and other metabolites that can cross the BBB and directly affect brain function[9][28][19].

1.4 Gut-brain axis in health and disease

In healthy individuals, the MGBA maintains a dynamic equilibrium characterized by microbial diversity, gut barrier integrity, balanced immune responses, and optimal neurotransmitter signaling[11][22]. A healthy gut microbiome exhibits resilience to perturbations, stable core microbiota composition, and symbiotic interactions with the host that promote both local and systemic homeostasis[22][23]. The production of beneficial metabolites by commensal bacteria supports intestinal barrier function, regulates immune responses, and influences neurodevelopment and cognitive function throughout the lifespan[9][28].
However, disruption of this delicate balance—termed dysbiosis—has been implicated in numerous neurological and psychiatric disorders, including AD, Parkinson's disease, multiple sclerosis, depression, and anxiety[29][30][8] Dysbiosis is characterized by decreased microbial diversity, altered bacterial composition with enrichment of pro-inflammatory species, reduced production of beneficial metabolites, and increased gut permeability (often referred to as "leaky gut")[29][30] These alterations can trigger a cascade of pathological events including systemic inflammation, immune dysregulation, BBB disruption, and neuroinflammation that collectively contribute to neurodegenerative processes[30][8].
The concept of the MGBA in neurodegenerative disease has gained substantial support from preclinical studies demonstrating that germ-free mice exhibit altered HPA axis responses to stress, abnormal anxiety-like behaviors, and impaired social cognition compared to conventionally colonized animals[32]. Remarkably, many of these behavioral and neurophysiological alterations can be rescued through microbial colonization, providing compelling evidence for the causal role of gut microbiota in brain function[33][9].
Similarly, antibiotic-induced depletion of gut microbiota in adult animals results in changes to neurotransmitter levels, altered gene expression in brain regions critical for emotion and cognition, and modifications to microglial morphology and function[9][28].The gut microbiota influences brain health through multiple mechanisms that operate across the lifespan. During early development, microbial colonization shapes the maturation of microglia, the brain's resident immune cells, influencing their surveillance functions and responses to injury[33][9] Throughout adulthood, the microbiota continues to modulate neurogenesis in the hippocampus, synaptic plasticity, neuroinflammation, and neurotransmitter metabolism[9].
In aging, age-related changes in microbiota composition—including decreased diversity and shifts in phylum-level abundances—correlate with cognitive decline and increased susceptibility to neurodegenerative diseases[33]

1.5 Objectives and scope of the review gut microbiota and its role in brain function

The primary objective of this comprehensive review is to critically examine the current state of knowledge regarding the role of gut microbiota dysbiosis in the pathogenesis and progression of AD. Despite intensive research over the past decade, the precise mechanisms by which microbial imbalances contribute to AD remain incompletely understood, and the therapeutic potential of microbiota-targeted interventions requires rigorous evaluation.

This review aims to synthesize evidence from human clinical studies, animal models, and mechanistic investigations to provide a cohesive framework for understanding the complex interplay between gut dysbiosis and AD pathology.Specifically, this review will address several critical questions:

(1) What compositional and functional alterations characterize the gut microbiome in AD patients compared to cognitively healthy individuals?

(2) Through what specific mechanisms do gut microbiota and their metabolites influence AD-related pathological processes, including amyloid deposition, tau pathology, neuroinflammation, and cognitive decline?

(3) What evidence exists from animal models regarding the causal relationship between gut dysbiosis and AD progression?

(4) What are the specific microbial signatures or biomarkers that may enable early detection or risk stratification for AD?

(5) What therapeutic strategies targeting the MGBA show promise for preventing or slowing AD progression?

The scope of this review encompasses four main areas of investigation. First, we will examine the

1.6 Composition and functions of the healthy gut microbiome

The healthy human gut microbiome is a diverse and dynamic community predominantly comprised of bacteria from the phyla Bacteroidota and Bacillota, which together constitute the majority of the microbial population. This microbiota plays a fundamental role in maintaining host health by facilitating digestion of complex carbohydrates, synthesizing essential vitamins, modulating immune responses, and preserving gut barrier integrity. Through production of key metabolites such as short-chain fatty acids, the microbiome also influences systemic physiology and contributes to brain health via the gut-brain axis. Maintaining a balanced and diverse microbial ecosystem is critical for overall health, with disruptions linked to a wide range of diseases.[34]

1.7 Microbiota-derived metabolites and brain function[eg:Scfas, tryptophan, and bile acids]

SCFAs, produced primarily via fermentation of dietary fibers, regulate not only local immune responses but also the activation of microglia in the brain—a vital facet of neurodegeneration and repair [35][36]. Tryptophan metabolites, such as kynurenine, participate in modulating neuroinflammation and are closely linked to cognitive performance. Bile acids, once considered simple digestive agents, have emerged as signaling molecules affecting both the gut environment and central neural function[37]

1.8 Influence on neuroinflammation and neurotransmission

Microbiota-derived neuroactive molecules (serotonin, dopamine, GABA, and others) modulate host neurotransmitter pools and can reach the brain either directly or by controlling afferent neural traffic. These metabolites can incite or suppress neuroinflammatory cascades, alter blood-brain barrier permeability, and even affect deposition of amyloid-beta[38].IV. Dysbiosis in Alzheimer's Disease.

1.9 Human studies—microbial signatures

Clinical studies consistently report reduced microbial diversity in AD patients, with decreased Firmicutes and Bifidobacterium, and reciprocal increases in pro-inflammatory taxa like Escherichia and Proteobacteria[39]. These changes correlate with disease severity and cognitive scores, but remain subject to geographic, dietary, and methodological differences that necessitate standardized, large-scale trials[39].

1.10 Animal model evidence

Experimental findings in genetically susceptible mouse models show that manipulating gut microbiota through antibiotics, dietary shifts, or fecal transplantation can dramatically modify amyloid and tau load in the brain[40]. These interventions recalibrate systemic and CNS immune activation, reinforce BBB function, and reduce neurodegeneration, strengthening the causal argument for dysbiosis as a driver of AD progression.

1.11 Biomarkers and specific microbial patterns

Emerging research is focused on identifying reproducible microbial "signatures" as early warning markers for AD risk. Specific taxa and functional gene profiles—such as deficiencies in butyrate-producing Faecalibacterium and Akkermansia, or overrepresentation of pro-inflammatory Proteobacteria—are proposed as potential diagnostic and prognostic tools[41].

Etiology /pathophysiological mechanisms linking dysbiosis to AD

Dysbiosis contributes to Alzheimer's disease (AD) through converging immunological, vascular, metabolic, and proteostatic mechanisms, and the same mechanistic framework underpins lifestyle links, microbiome- targeted therapies, research gaps, and future AI- enabled directing.[42][43][44]



Figure 1. Gut microbiota and dysbiosis in Alzheimer's disease: implications for pathogenesis and treatment. Aging Dis. 2020;11(6):1436–1448. doi:10.14336/AD.2020.0224. PMID: 32829453.

2. Neuroinflammation and microglial activation

Gut dysbiosis reshapes microbial composition toward pro-inflammatory taxa, increases Gram-negative bacteria and lipopolysaccharide (LPS) load, and alters microbial metabolites, driving chronic systemic low-grade inflammation.[44][45] Circulating LPS and bacterial amyloids engage pattern-recognition receptors (TLR2, TLR4, NLRP3 inflammasome) on microglia and astrocytes, triggering cytokine cascades (e.g., IL-1β, IL-6, TNF-α), complement activation, and synaptic pruning that accelerate neuronal loss and cognitive decline in AD models.[46][43].

Microbiota also modulate trafficking and phenotype of gut-primed immune cells (e.g., IL-17-producing γδ-T cells, Th17 cells) into meninges and brain, further amplifying neuroinflammation and disturbing synaptic plasticity, BDNF expression, and neurotransmitter balance.[47][44]

2.1. Blood–brain barrier disruption

Short-chain fatty acids (SCFAs) such as butyrate, propionate, and acetate support tight junction protein expression and endothelial health, but dysbiosis reduces SCFA producers and enriches species that release barrier-disruptive metabolites.[48][42]This imbalance compromises intestinal and blood–brain barrier (BBB) integrity, increasing permeability ("leaky gut" and "leaky brain") and facilitating entry of LPS, peripheral cytokines, and immune cells into the CNS, which fuels neuroinflammation and accelerates AD pathology.[48][42]

Experimental models show that microbiota manipulation (germ-free, antibiotic-treated, or probiotic-supplemented animals) alters BBB tight junction proteins and permeability, supporting a causal role for gut microbes in early BBB dysfunction linked to cognitive impairment.[48][47]

2.2 Amyloid-β and tau pathology

Dysbiosis can enhance amyloidogenic processing of amyloid precursor protein (APP) via inflammatory signaling, oxidative stress, and altered lipid metabolism, increasing brain Aβ production and plaque burden.[42][45] Certain gut bacteria produce amyloid-like proteins and cross-reactive antigens that may promote peripheral immune priming and cross-seeding of host Aβ, while systemic inflammation impairs Aβ clearance across the BBB and via glymphatic routes.[49][43]

Microbiota-driven inflammatory and metabolic changes also favor tau hyperphosphorylation (e.g., via kinase activation and mitochondrial stress), aggregation into neurofibrillary tangles, and synaptic damage, linking dysbiosis to both hallmark AD pathologies in preclinical and clinical studies.[49][42]

2.3 Mitochondrial dysfunction and oxidative stress; influence of lifestyle and environment

Gut dysbiosis shifts microbial metabolites and host redox balance, increasing ROS, reactive nitrogen species, and mitochondrial damage in neurons and glia, which in turn exacerbates Aβ aggregation, tau pathology, and synapse loss.[50][51] Diets rich in saturated fat and sugar, sedentary lifestyle, and chronic psychological stress intensify mitochondrial dysfunction and oxidative stress, often in parallel with dysbiosis and metabolic syndrome, thereby magnifying AD risk and progression.[42][45]Reduced levels of neuroprotective metabolites (SCFAs, indole derivatives, antioxidant compounds) and impaired mitochondrial biogenesis pathways (e.g., PGC-1α) form a mechanistic bridge between adverse lifestyle, gut imbalance, and neuronal energetic failure in AD.[42][51]

Mitochondrial dysfunction and oxidative stress are closely interconnected processes that play a crucial role in the development and progression of many chronic and neurodegenerative diseases. Mitochondria are essential organelles responsible for producing cellular energy in the form of ATP through oxidative phosphorylation.

During this process, small amounts of reactive oxygen species (ROS) are naturally generated as byproducts. Under normal conditions, these ROS are neutralized by the body's antioxidant defense systems. However, when mitochondrial function becomes impaired, excessive ROS are produced, overwhelming the antioxidant capacity and leading to oxidative stress. This imbalance damages cellular components such as lipids, proteins, and DNA, ultimately disrupting normal cellular function and promoting cell death.

Mitochondrial dysfunction can arise from multiple factors, including genetic mutations, aging, and environmental influences. Damaged mitochondria exhibit reduced efficiency in energy production and increased leakage of electrons, which further enhances ROS generation. This creates a vicious cycle where oxidative stress further damages mitochondrial structures, including mitochondrial DNA (mtDNA), impairing their function even more. In the brain, which has high energy demands, such dysfunction significantly contributes to neuronal damage, synaptic loss, and cognitive decline.

Lifestyle and environmental factors have a profound influence on mitochondrial health and oxidative balance. Diet plays a key role; consumption of high-fat, high-sugar, and processed foods increases oxidative stress and impairs mitochondrial efficiency, whereas diets rich in antioxidants (such as fruits, vegetables, and polyphenols) help protect mitochondria and reduce ROS levels. Physical activity is another important factor—regular exercise enhances mitochondrial biogenesis and improves antioxidant defenses, while a sedentary lifestyle promotes mitochondrial decline. Chronic psychological stress can also elevate cortisol levels, leading to increased oxidative stress and mitochondrial damage. Additionally, environmental exposures such as air pollution, heavy metals, pesticides, and toxins can directly impair mitochondrial function and increase ROS production.

Aging further exacerbates these processes, as mitochondrial efficiency naturally declines over time and antioxidant defenses weaken. This makes older individuals more susceptible to oxidative damage and related diseases. Overall, mitochondrial dysfunction and oxidative stress are central to disease mechanisms, but they are also significantly modifiable through lifestyle choices. Maintaining a balanced diet, engaging in regular physical activity, reducing stress, and minimizing exposure to environmental toxins are key strategies for preserving mitochondrial health and preventing oxidative damage.

Mitochondrial dysfunction is a condition in which the mitochondria lose their ability to efficiently produce energy, leading to reduced ATP generation and increased production of harmful reactive oxygen species (ROS). Normally, mitochondria act as both energy producers and regulators of cellular metabolism, but when they become damaged, they shift from being beneficial to harmful. This dysfunction not only reduces cellular energy supply but also disturbs calcium balance, apoptosis (programmed cell death), and cellular signaling pathways. As a result, cells—especially high-energy-demanding cells like neurons—become more vulnerable to injury and degeneration.

Oxidative stress occurs when there is an imbalance between ROS production and antioxidant defense mechanisms. Instead of being neutralized, excess ROS attack cellular structures, including mitochondrial membranes, proteins, and DNA. One important consequence is damage to mitochondrial DNA (mtDNA), which lacks strong repair mechanisms compared to nuclear DNA. This makes mitochondria highly susceptible to oxidative damage, further worsening their function and creating a self-perpetuating cycle of damage and stress.

Lifestyle factors strongly influence mitochondrial health. Poor dietary habits, especially excessive intake of processed foods, trans fats, and refined sugars, can increase oxidative burden and impair mitochondrial enzymes. On the other hand, nutrient-rich diets containing antioxidants like vitamins C and E, flavonoids, and omega-3 fatty acids support mitochondrial integrity and reduce oxidative damage.

Hydration and micronutrient balance (such as magnesium and coenzyme Q10) are also essential for optimal mitochondrial function.

Environmental factors further contribute to mitochondrial damage. Exposure to pollutants, radiation, cigarette smoke, and industrial chemicals increases the production of free radicals, directly affecting mitochondrial structure and efficiency. In addition, long-term use of certain drugs and toxins can interfere with mitochondrial respiration and accelerate oxidative injury.



2.4 Diet and nutrition

Mediterranean-style diets rich in fiber, polyphenols, omega-3 fatty acids, and minimally processed foods are associated with greater microbial diversity, higher SCFA production, lower systemic inflammation, and reduced AD risk or slower cognitive decline.[42][45] In contrast, Western diets characterized by high saturated fat, refined carbohydrates, and low fiber drive dysbiosis, promote endotoxemia, insulin resistance, and inflammation, thereby worsening amyloid and tau pathology in experimental models.[42][51]

Specific nutrients and phytochemicals (e.g., prebiotic fibers, flavonoids, resveratrol, curcumin) can modulate gut composition and microbial metabolism, offering an avenue to indirectly regulate neuroinflammation, Aβ handling, and synaptic resilience.[42][51]

2.5 Antibiotics and medications

Broad-spectrum antibiotics and chronic polypharmacy disrupt microbial diversity and resilience, often depleting beneficial commensals and enabling opportunistic

overgrowth, which can reverberate along the gut–brain axis.[46][52]In animal studies, antibiotic treatment can both attenuate and exacerbate pathology depending on timing, spectrum, and duration, highlighting the need for careful evaluation of long-term effects of antimicrobial and gut-active drugs in populations at risk for AD.[46][47]
Other medications commonly used in older adults, such as proton-pump inhibitors, antidiabetics, and psychotropics, also remodel the gut microbiome, potentially interacting with AD risk and progression in ways that remain incompletely characterized.[42][53]

2.6 Aging and comorbidities

Aging naturally reduces microbial diversity and shifts the gut ecosystem toward pro-inflammatory, pathobiont-enriched communities, coinciding with "inflammaging" and increased vulnerability to neurodegeneration.[47][52]
Comorbidities such as obesity, type 2 diabetes, cardiovascular disease, and frailty are associated with characteristic dysbiotic patterns, impaired barrier function, and systemic inflammation, collectively amplifying the risk and severity of cognitive decline and AD.[42][45]
Meta-analyses indicate that individuals within the AD spectrum exhibit distinct gut microbial signatures compared with cognitively normal controls, and some taxa correlate with clinical severity and neuropsychiatric symptoms, suggesting biomarker potential.[52][45]

3. Therapeutic implications and interventions

3.1 Probiotics and prebiotics

Preclinical studies demonstrate that specific probiotic strains (e.g., Bifidobacterium, Lactobacillus consortia) can reduce Aβ deposition, attenuate microglial activation, improve synaptic markers, and enhance memory performance in AD models.[54][51]Small human trials report that multi-strain probiotic supplementation, sometimes combined with prebiotic fibers, improves certain cognitive domains, metabolic parameters, and inflammatory markers in patients with mild cognitive impairment or early AD, though effect sizes and reproducibility vary.[53][51]
Mechanistically, probiotics and prebiotics are thought to restore eubiosis, increase SCFAs, modulate tryptophan–serotonin pathways, reinforce gut and BBB barriers, and reshape immune responses toward a more anti-inflammatory profile.[51][54]

3.2 Fecal microbiota transplantation (fmt)

FMT aims to reset the gut ecosystem by transferring stool from healthy donors, and case reports and small feasibility studies suggest potential cognitive benefits and microbiome normalization in dementia patients, including AD.[55][49] Early clinical studies indicate that oral or colonoscopic FMT is generally safe in older adults under controlled conditions, but standardized protocols, donor selection criteria, and long-term outcomes are still inadequately defined.[55][51]
Animal experiments support FMT from young or healthy donors as a means to reduce neuroinflammation and Aβ pathology, but translating optimal timing, dosing, and patient selection to human AD remains a major research frontier.[49][51]

3.3 Dietary interventions (mediterranean, ketogenic)

Mediterranean dietary patterns have been linked to favorable microbiome profiles, reduced systemic and CNS inflammation, better vascular health, and slower cognitive decline in observational cohorts and some interventional trials.[42][45] Ketogenic and low-carbohydrate diets may improve mitochondrial efficiency, reduce excitotoxicity, alter gut microbiota, and provide alternative energy substrates (ketone bodies) for the hypometabolic AD brain, though long-term adherence and safety require careful monitoring.[42][51]
Personalized nutrition approaches that integrate microbiome profiles, metabolic status,

and genetic risk (e.g., APOE genotype) are being explored to optimize dietary strategies for AD prevention and management.[42][56]

3.4 Targeting microbial metabolites

Strategies to increase beneficial SCFAs (via diet, targeted probiotics, or SCFA prodrugs) or modulate bile acids, indoles, and other microbial metabolites are under investigation as ways to dampen neuroinflammation, stabilize the BBB, and support synaptic plasticity.[51][42] Inhibiting harmful metabolites (e.g., LPS-associated endotoxemia, certain secondary bile acids, trimethylamine-N-oxide) or their signaling pathways may reduce oxidative stress, vascular dysfunction, and amyloid pathology.[51][45]

Drug discovery efforts increasingly consider microbial enzymes and metabolic pathways as therapeutic targets, opening possibilities for small molecules that selectively reprogram the microbiome–metabolite–brain axis in AD.[51][55]

4. Challenges, limitations, and gaps

4.1 Variability in study design and methodology

Differences in sequencing platforms, taxonomic pipelines, sample collection, and normalization approaches contribute to inconsistent microbial signatures across AD studies, complicating meta-analysis and biomarker development.[42][53] Clinical studies often feature small sample sizes, cross-sectional designs, inadequate control of confounders (diet, medications, comorbidities), and heterogeneous diagnostic criteria, limiting generalizability.[43][45]

4.2 Causality vs. Correlation

Most human data are associative, and whether dysbiosis is a cause, consequence, or epiphenomenon of AD remains unresolved; reverse causality via AD-related changes in diet, activity, and medication use is plausible.[57][58]Germ-free, antibiotic, and FMT experiments in animals support a contributory role of the microbiome, but species differences and artificial experimental conditions mean that causal inferences cannot yet be fully extrapolated to humans.[47][52]

4.3 Translational and clinical challenges

Inter-individual variability in microbiome composition, host genetics, environmental exposures, and disease stage demands personalized approaches, yet most interventions are still "one-size-fits-all."[42][51] Regulatory, manufacturing, and safety frameworks for live biotherapeutics, FMT products, and long-term microbiome modulation are still evolving, delaying large-scale implementation in AD care.[51][54]

5. Future directions and research priorities

5.1 Longitudinal studies, personalized therapies, multi-omics, and AI

Large, well-phenotyped longitudinal cohorts with serial microbiome, metabolome, imaging, and cognitive assessments are needed to map temporal trajectories and disentangle causal links between dysbiosis and AD phenoconversion.[42][45]Personalized microbiome-based therapies may combine probiotics, diet, FMT, and small molecules tailored to individual microbial, metabolic, and genetic profiles, moving from empirical to precision interventions.[51][54]

Integration of multi-omics—metagenomics, metatranscriptomics, metabolomics, proteomics, and host genomics—with advanced machine learning can identify microbial signatures and metabolic networks predictive of dysbiosis, mild cognitive impairment, and AD progression, and support decision tools for clinical risk stratification and treatment response.[59][60]AI approaches, including deep learning and network-based models, are being explored to simulate gut–brain interactions, prioritize therapeutic targets, and optimize clinical trial design for

microbiome- focused AD therapies.[59][51]

6. Conclusion

Alzheimer's disease (AD) remains one of the most challenging neurodegenerative disorders, marked by progressive cognitive decline, synaptic dysfunction, accumulation of amyloid-β plaques, and hyperphosphorylated tau tangles. Traditional views of AD pathogenesis focused primarily on central nervous system pathology, yet mounting evidence indicates that systemic factors, particularly the gut microbiota, play a crucial role in modulating disease onset and progression. The gut-brain axis, a bidirectional communication network connecting the enteric nervous system, central nervous system, immune system, and microbiota, has emerged as a central player in maintaining neural homeostasis and influencing neuroinflammation, neurotransmission, and blood-brain barrier integrity.

A healthy gut microbiome exerts neuroprotective effects through the production of key metabolites, including short-chain fatty acids (SCFAs), tryptophan derivatives, bile acids, and other microbial metabolites. These compounds modulate microglial activity, regulate inflammatory signaling, and influence neurotransmitter synthesis. Dysbiosis, characterized by decreased microbial diversity, overgrowth of pathogenic taxa, and altered metabolite profiles, has been consistently associated with AD. Human studies and animal models have demonstrated that dysbiotic gut communities can exacerbate neuroinflammatory responses, compromise the blood-brain barrier, promote amyloid-β deposition, impair tau clearance, and increase oxidative stress and mitochondrial dysfunction, collectively accelerating neurodegenerative processes.

Environmental and lifestyle factors further influence the microbiome's composition and function, thereby affecting AD risk. Diet, nutritional status, long-term antibiotic exposure, comorbidities, and aging contribute to microbial shifts that may either exacerbate or mitigate disease progression. These insights highlight the complex interplay between host, environment, and microbiota, suggesting that AD pathogenesis is not solely confined to neuronal pathology but involves systemic dysregulation.

From a therapeutic perspective, targeting the gut microbiome represents a novel and promising avenue. Interventions such as probiotics, prebiotics, fecal microbiota transplantation (FMT), dietary modifications (e.g., Mediterranean or ketogenic diets), and modulation of microbial metabolites have demonstrated potential in restoring microbial balance, reducing neuroinflammation, and improving cognitive function in preclinical studies. These approaches underscore the importance of moving beyond symptomatic management to strategies that address upstream modulators of AD.

Despite significant advances, there remain several challenges and knowledge gaps. Most studies are limited by small sample sizes, cross-sectional designs, and variability in microbiome analysis techniques. Establishing causality between dysbiosis and AD, translating preclinical findings to human populations, and identifying reliable microbial biomarkers for early detection are critical areas for future research. Integration of multi-omics approaches, including metagenomics, metabolomics, transcriptomics, and proteomics, alongside artificial intelligence and machine learning, offers a promising path to uncover mechanistic links, predict disease risk, and develop personalized microbiome-based therapies.

In conclusion, the gut-brain axis and microbial dysbiosis represent key modulators of Alzheimer's disease, offering a paradigm shift in our understanding of neurodegeneration. By elucidating the mechanisms linking microbial imbalance to neuroinflammation, amyloid/tau pathology, and cognitive decline, researchers can develop innovative diagnostic and therapeutic strategies. Future studies focusing on longitudinal human cohorts, personalized interventions, and integrative computational models hold the potential to transform AD management, enabling early intervention,

disease modification, and ultimately, a significant improvement in patient quality of life. This integrative perspective reinforces that maintaining a healthy gut microbiota is not only central to gastrointestinal health but may also be critical for preserving cognitive function and delaying the onset of Alzheimer's disease.

References

1. Gut microbiota-driven neuroinflammation in Alzheimer's disease: https://pmc.ncbi.nlm.nih.gov/articles/PMC12241022/
2. Microbiota–gut–brain axis in neurodegenerative diseases: https://pmc.ncbi.nlm.nih.gov/articles/PMC12436269/
3. The link between gut microbiome and Alzheimer's disease: https://pubmed.ncbi.nlm.nih.gov/38940631/
4. Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases: https://www.nature.com/articles/s41392-024-01743-1
5. Gut-Brain Axis Structure and Mechanisms:Microbiota-gut-brain axis and the central nervous system: https://pmc.ncbi.nlm.nih.gov/articles/PMC5581153/
6. Interactions between the microbiota, immune and nervous systems: https://pmc.ncbi.nlm.nih.gov/articles/PMC6960010/
7. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems: https://pmc.ncbi.nlm.nih.gov/articles/PMC4367209/
8. Regulation of Neurotransmitters by the Gut Microbiota and Effects on Cognition: https://pmc.ncbi.nlm.nih.gov/articles/PMC8234057/
9. Short-Chain Fatty Acids (SCFAs):The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication: https://pmc.ncbi.nlm.nih.gov/articles/PMC7005631/
10. The Role of Short-Chain Fatty Acids in Microbiota–Gut–Brain Communication: https://pmc.ncbi.nlm.nih.gov/articles/PMC10606032/
11. Short chain fatty acids: Microbial metabolites for gut-brain axis communication: https://www.sciencedirect.com/science/article/pii/S0303720722000193
12. Tryptophan and Bile Acid Metabolism:Tryptophan Metabolism: A Link Between the Gut Microbiota and the Brain: https://www.sciencedirect.com/science/article/pii/S2161831322002952
13. Bile Acids: A Communication Channel in the Gut-Brain Axis: https://pubmed.ncbi.nlm.nih.gov/33085065/
14. Bile acid modulation by gut microbiota: https://pmc.ncbi.nlm.nih.gov/articles/PMC11374218/
15. Human Studies on AD and Microbiome:Gut microbiome alterations in Alzheimer's disease: https://www.nature.com/articles/s41598-017-13601-y
16. Signature of Alzheimer's Disease in Intestinal Microbiome: https://pmc.ncbi.nlm.nih.gov/articles/PMC9063165/
17. Gut microbiota changes in patients with Alzheimer's disease spectrum: https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2024.1422350/full
18. Current understanding of the Alzheimer's disease-associated microbiome: https://www.nature.com/articles/s12276-023-01146-2
19. Animal Model Studies:Altered Gut Microbiota in a Mouse Model of Alzheimer's Disease: https://pubmed.ncbi.nlm.nih.gov/29036812/
20. Fecal microbiota transplantation alleviated Alzheimer's disease-like pathology: https://www.nature.com/articles/s41398-019-0525-3
21. The gut microbiome in Alzheimer's disease: what we know and what remains to be explored: https://pmc.ncbi.nlm.nih.gov/articles/PMC9889249/
22. Neuroinflammation and Blood-Brain Barrier:Blood-Brain Barrier Dysfunction Amplifies the Development of Neuroinflammation: https://pmc.ncbi.nlm.nih.gov/articles/PMC8475767/

23. Lipopolysaccharide Alters the Blood-brain Barrier Transport: https://pmc.ncbi.nlm.nih.gov/articles/PMC2783557/
24. Blood-Brain Barrier Disruption by Lipopolysaccharide and Sepsis-Associated Encephalopathy: https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2021.768108/full
25. Therapeutic Interventions:The effects of probiotics, prebiotics, and fecal microbiota transplantation on cognitive function: https://pubmed.ncbi.nlm.nih.gov/34754163/
26. Fecal microbiota transplantation: a novel strategy for treating Alzheimer's disease: https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2023.1281233/full
27. The Neuroprotective Effect of Short-chain Fatty Acids Against Hypoxia: https://pmc.ncbi.nlm.nih.gov/articles/PMC7876449/
28. Specific Bacterial Species:Identification of Faecalibacterium prausnitzii strains for gut microbiome-based intervention: https://pubmed.ncbi.nlm.nih.gov/34622235/
29. Akkermansia muciniphila in neuropsychiatric disorders: https://pmc.ncbi.nlm.nih.gov/articles/PMC10363720/
30. Faecalibacterium: a bacterial genus with promising human health applications: https://academic.oup.com/femsre/article/47/4/fuad039/7224591
31. The Amyloid-β Pathway in Alzheimer's Disease: https://www.nature.com/articles/s41380-021-01249-0
32. Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's disease: https://www.ijbs.com/v17p2181.htm
33. What defines a healthy gut microbiome? Gut: https://gut.bmj.com/content/73/11/1893
34. SCFAs and brain communication: https://pmc.ncbi.nlm.nih.gov/articles/PMC7005631/https://pmc.ncbi.nlm.nih.gov/articles/PMC10606032
35. Tryptophan metabolism and neuroinflammation: https://www.sciencedirect.com/science/article/pii/S2161831322002952
36. Bile acids as signaling molecules: https://pmc.ncbi.nlm.nih.gov/articles/PMC11374218/https://pubmed.ncbi.nlm.nih.gov/33085065/
37. Microbiota-gut-brain axis in neurodegeneration: https://pmc.ncbi.nlm.nih.gov/articles/PMC12436269/
38. Gut microbiome changes in AD:https://www.nature.com/articles/s41598-017-13601- https://pmc.ncbi.nlm.nih.gov/articles/PMC9889249
39. Mouse model gut microbiota manipulation: https://pubmed.ncbi.nlm.nih.gov/29036812/https://www.nature.com/articles/s41398-019-0525-3
40. Microbial biomarkers in AD: https://pmc.ncbi.nlm.nih.gov/articles/PMC9063165/
41. The gut microbiome and Alzheimer's disease - ScienceDirect.com https://www.sciencedirect.com/science/article/abs/pii/S0149763422003037
42. The Microbiota–Gut–Brain Axis in Alzheimer's Disease: A Review of https://pmc.ncbi.nlm.nih.gov/articles/PMC9035085/
43. Emerging role of gut microbiota dysbiosis in neuroinflammation and ... https://pmc.ncbi.nlm.nih.gov/articles/PMC10225576/
44. Implications of the Gut Microbiome in Alzheimer's Disease https://www.cureus.com/articles/300275-implications-of-the-gut-microbiome-in-alzheimers-disease-a-narrative-review
45. Emerging role of gut microbiota dysbiosis in neuroinflammation and ... https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2023.1149618/full

46. The gut microbiome and Alzheimer's disease - PubMed Central - NIH https://pmc.ncbi.nlm.nih.gov/articles/PMC9637435/
47. Gut dysbiosis is associated with increased blood–brain barrier ... https://pmc.ncbi.nlm.nih.gov/articles/PMC12380634/
48. Full article: Gut-derived β-amyloid: Likely a centerpiece of ... https://www.tandfonline.com/doi/full/10.1080/19490976.2023.2167172
49. oxidative stress and the path to cognitive dysfunction https://www.tandfonline.com/doi/full/10.1080/17582024.2025.2510175?src=exp-la
50. Gut microbiota metabolites: potential therapeutic targets for ... https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1459655/full
51. The Microbiota–Gut–Brain Axis and Alzheimer's Disease https://pmc.ncbi.nlm.nih.gov/articles/PMC7824474/
52. Gut microbiota in patients with Alzheimer's disease spectrum https://www.aging-us.com/article/203826/text
53. Exploring the potential of probiotics in Alzheimer's disease and gut ... https://www.sciencedirect.com/science/article/pii/S2667242124000988
54. Oral Fecal Microbiota Transplant Feasibility Study in ... https://www.clinicaltrials.gov/study/NCT03998423
55. The link between gut microbiome and Alzheimer's disease: From the ... https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14057
56. Does gut microbiota dysbiosis directly cause neurodegeneration? https://consensus.app/search/does-gut-microbiota-dysbiosis-directly-cause-neuro/ejtRWGhQRO-oAE8IuCFtaA/
57. The Microbiota-Gut-Brain Axis in Alzheimer's Disease - PubMed - NIH https://pubmed.ncbi.nlm.nih.gov/35202456/
58. Microbiota–gut–brain axis and its therapeutic applications ... - Nature https://www.nature.com/articles/s41392-024-01743-1
59. The impact of the microbiota-gut-brain axis on Alzheimer's disease ... https://observatorio.fm.usp.br/entities/publication/36f156a7-9eff-4e0e-9c83-04a338c3fae3